` H02 (Haw Par Corporation Ltd) vs NOVO B (Novo Nordisk A/S) Comparison - Alpha Spread
Dashboard Tools Market News Investing Ideas Pricing
Search 100,000+ stocks...
Sign Up
Log in

H02
vs
NOVO B

Over the past 12 months, H02 has significantly outperformed NOVO B, delivering a return of +34% compared to the NOVO B's 35% drop.

Valuation Growth Profitability Solvency Stocks Performance
Start AI Comparison

Smart Verdict
AI-Powered

Not Sure Which Stock Wins?
Let AI Decide.
H02
NOVO B
One-click summary across all key metrics.
Ranked results with clear takeaways.
No spreadsheets, no guesswork.
One-click summary across all key metrics.
Ranked results with clear takeaways.
No spreadsheets, no guesswork.
Start AI Comparison
Smart Verdict is Ready!
See Who Stands Out.
All the numbers, charts, and metrics summarized into one smart verdict.
Stocks Compared:
H02 NOVO B
Show Comparison Results
Summarizing...
We need a little more time to summarize the results

Valuation Comparison

H02 Intrinsic Value
10.6 SGD
Overvaluation 39%
Intrinsic Value
Price S$17.25
NOVO B Intrinsic Value
445.31 DKK
Undervaluation 41%
Intrinsic Value
Price kr262
Company Last Price Intrinsic Value DCF Value Multiples-Based Value Wall St Target
Haw Par Corporation Ltd
SGX:H02
17.25 SGD
Novo Nordisk A/S
CSE:NOVO B
262 DKK
No Stocks Selected

Compare the stock's valuation with its competitors.

Select Stocks to Compare
Valuation Scenario:
Bear Case
Base Case
Bull Case

Growth Comparison

Growth Over Time
H02, NOVO B

H02
NOVO B
Add Stock
Revenue
www.alphaspread.com
No Stocks Selected

Compare company's financials with its competitors.

Select Stocks to Compare
Company LTM Historical Growth Growth Streak % Positive Years Max Drawdown Volatility Forecasted Growth
3 Years 5 Years 10 Years 1 Year 3 Years
Haw Par Corporation Ltd
Revenue
Novo Nordisk A/S
Revenue

All metrics are calculated based on data from the last 10 years.

No Stocks Selected

Compare company's financials with its competitors.

Select Stocks to Compare

Profitability Comparison

Free Cash Flow
H02, NOVO B

H02
NOVO B
Add Stock
Free Cash Flow
www.alphaspread.com
No Stocks Selected

Compare company's free cash flow with its competitors.

Select Stocks to Compare
Company LTM Average Historical Growth FCF Margin Conversion
3 Years 5 Years 3 Years 5 Years 10 Years
Haw Par Corporation Ltd
SGX:H02
Novo Nordisk A/S
CSE:NOVO B
No Stocks Selected

Compare company's free cash flow with its competitors.

Select Stocks to Compare
What is Free Cash Flow?

Gross Margin

H02
56%
NOVO B
81%

Operating Margin

H02
30.2%
NOVO B
41.3%

Net Margin

H02
115.4%
NOVO B
33.1%

FCF Margin

H02
23.9%
NOVO B
9.4%

ROE

H02
6.3%
NOVO B
60.7%

ROA

H02
6.1%
NOVO B
20.3%

ROIC

H02
1.9%
NOVO B
22.1%

ROCE

H02
1.6%
NOVO B
44.4%

Solvency Comparison

Haw Par Corporation Ltd
Equity Waterfall
Assets
Liabilities
Equity
What is Equity Waterfall?
Novo Nordisk A/S
Equity Waterfall
Assets
Liabilities
Equity
What is Equity Waterfall?
No Stocks Selected

Compare company's equity waterfall with its competitors.

Select Stocks to Compare
Balance Sheet Comparison
No Stocks Selected

Compare company's balance sheet with its competitors.

Select Stocks to Compare

Stocks Performance

Stocks Performance
H02, NOVO B

Loading
H02
NOVO B
Add Stock
www.alphaspread.com
1Y 3Y 5Y 10Y 15Y 20Y
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
H02, NOVO B

Loading
H02
NOVO B
Difference
www.alphaspread.com
1Y 3Y 5Y 10Y 15Y 20Y

Performance By Year
H02, NOVO B

Loading
H02
NOVO B
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
Not Sure Which Stock Wins?
Let AI Decide
One-click summary across all key metrics.
Ranked results with clear takeaways.
No spreadsheets, no guesswork.
Start AI Comparison
Compare H02 to other stocks
LLY
Eli Lilly and Co
Cheaper
vs H02
JNJ
Johnson & Johnson
Cheaper
vs H02
ROG
Roche Holding AG
Cheaper
vs H02
AZN
AstraZeneca PLC
More expensive
vs H02
Unlock Full Access to Alpha Spread
Create Free Account
ALPHA SPREAD
Follow us
Join more than 332,500+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.

AI Assistant
Get AI-powered insights for any company or topic.
Open AI Assistant
Other Tools
Stock Screener
Discover stocks
Stock Comparison
Smarter decisions through side-by-side analysis
Intrinsic Value Calculator
Discover the true worth of your stocks
DCF Value Calculator
Harness the power of DCF

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett